Befiradol

Drug Profile

Befiradol

Alternative Names: F-13640; NLX 112

Latest Information Update: 22 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pierre Fabre
  • Developer Neurolixis
  • Class Antiparkinsonians; Non-opioid analgesics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Preclinical Drug-induced dyskinesia
  • Discontinued Cancer pain; Neuropathic pain

Most Recent Events

  • 14 Jun 2017 Pharmacodynamics data from preclinical trials in Drug-induced dyskinesia released by Neurolixis
  • 06 Feb 2015 Befiradol is available for licensing as of 06 Feb 2015. http://www.neurolixis.com/en/
  • 08 Aug 2014 Neurolixis plans a phase II trial for Drug-induced dyskinesia (Levodopa-induced dyskinesia in patients with Parkinson's disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top